PDA Midwest: Phase Appropriate Quality Oversight for Cell and Gene Therapy

Online
Register Now
Ask a Question

PDA Midwest Chapter invites you to learn about phase appropriate quality oversight for cell and gene therapy.

In the growing field of Cell and Gene Therapy, the question of what appropriate Quality Oversite at various clinical phases should be.  Too little oversight can affect the quality and robustness of the product.  Too much oversight stalls innovation and creates unnecessary hurdles that may be difficult to overcome when developing quality systems and controls for investigational cell and gene therapies. As Cell & Gene Therapies are administered to patients in all phases of trials, clinical supplies must be manufactured under conditions that meet cGMP requirements appropriate for the phase of manufacturing.


Sponsorship Opportunities

The PDA Midwest Chapter is very grateful to our dedicated members and sponsors for their continued interest, participation and support. We truly appreciate the generosity of our sponsors over the years, for without you, we could not provide this level of activity for our members.

Sponsorship includes:

  • 2-minute pre-recorded commercial video during the webinar
  • Recognition in email/social media correspondence of webinar

November Webinar Sponsorship: $275.00

More information coming soon.

Day 1

  • 11:00 am-11:10 am| Opening, Presenter Introduction
  • 11:10 am- 11:45 am| Speaker – Andrea M. Biggs, Director of Quality – Cell & Gene Therapy, Pharma Services Group of ThermoFisher Scientific
  • 11:45 am- 12:00 pm| Q&A From Audience to Presenter
  • 12:00 pm| Closing
Agenda is subject to change.

PLEASE READ  PDA is not affiliated or contracted with any outside hotel contracting company. If someone other than PDA or the PDA chosen hotel contacts you suggesting that they represent any PDA event, they do not. It is PDA's recommendation that you book your hotel directly through the official PDA chosen hotel that is listed on our web site.